AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:OMCLOmnicell Stock Price, Forecast & News

$66.76
-0.15 (-0.22 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$66.65
Now: $66.76
$68.26
50-Day Range
$62.63
MA: $67.28
$72.33
52-Week Range
$54.24
Now: $66.76
$94.85
Volume355,753 shs
Average Volume301,275 shs
Market Capitalization$2.85 billion
P/E Ratio41.73
Dividend YieldN/A
Beta1.03
Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Read More
Omnicell logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$897.03 million
Cash Flow$3.81 per share
Book Value$20.16 per share

Profitability

Net Income$61.34 million

Miscellaneous

Employees2,700
Market Cap$2.85 billion
Next Earnings Date7/23/2020 (Estimated)
OptionableOptionable

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

Omnicell (NASDAQ:OMCL) Frequently Asked Questions

How has Omnicell's stock been impacted by COVID-19 (Coronavirus)?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OMCL shares have decreased by 13.8% and is now trading at $66.76. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Omnicell?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Omnicell.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Omnicell.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) issued its quarterly earnings results on Thursday, May, 7th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.51 by $0.15. The company had revenue of $229.69 million for the quarter, compared to analysts' expectations of $218.99 million. Omnicell had a net margin of 7.51% and a return on equity of 11.37%. The company's quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.61 earnings per share. View Omnicell's earnings history.

What price target have analysts set for OMCL?

8 brokers have issued twelve-month price targets for Omnicell's stock. Their forecasts range from $76.00 to $100.00. On average, they expect Omnicell's stock price to reach $85.00 in the next twelve months. This suggests a possible upside of 27.3% from the stock's current price. View analysts' price targets for Omnicell.

Has Omnicell been receiving favorable news coverage?

News stories about OMCL stock have trended negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Omnicell earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Omnicell.

Who are some of Omnicell's key competitors?

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Adobe (ADBE), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA) and Applied Materials (AMAT).

Who are Omnicell's key executives?

Omnicell's management team includes the following people:
  • Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)
  • Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)
  • Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)
  • Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)
  • Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 46)

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.09%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann. View institutional ownership trends for Omnicell.

Which major investors are buying Omnicell stock?

OMCL stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View insider buying and selling activity for Omnicell.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $66.76.

How big of a company is Omnicell?

Omnicell has a market capitalization of $2.85 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,700 workers across the globe.

What is Omnicell's official website?

The official website for Omnicell is www.omnicell.com.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.